Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

James L. Rubenstein, M.D., Ph.D., Eric D. Hsi, MD, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, MD, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2012) 120 (21): 301.

https://doi.org/10.1182/blood.V120.21.301.301

Published: 2012

Journal Articles

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Lale Kostakoglu, MD, MPH, Heiko Schoder, MD, Nathan Hall, MD, PhD, David J. Straus, MD, Jeffrey L Johnson, PhD, Lawrence Schwartz, MD, Ann LaCasce, MD, Sin-Ho Jung, PhD, Nancy L. Bartlett, MD, George P. Canellos, MD, Bruce D. Cheson, MD

Blood (2011) 118 (21): 3644.

https://doi.org/10.1182/blood.V118.21.3644.3644

Published: 2011

Journal Articles

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson, for Cancer and Leukemia Group B

Blood (2011) 117 (20): 5314–5320.

https://doi.org/10.1182/blood-2010-10-314260

Published: 2011

Journal Articles

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

James L. Rubenstein, M.D., Ph.D., Jeffrey L. Johnson, Sin-Ho Jung, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2010) 116 (21): 763.

https://doi.org/10.1182/blood.V116.21.763.763

Published: 2010

Journal Articles

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

David A. Rizzieri, MD, Jeffrey L Johnson, John C. Byrd, MD, Gerard Lozanski, MD, Bayard L. Powell, MD, Thomas C. Shea, MD, Sreenivasa Nattom, Eva Hoke, Bruce D. Cheson, MD, Richard Larson, M.D.

Blood (2010) 116 (21): 858.

https://doi.org/10.1182/blood.V116.21.858.858

Published: 2010

Journal Articles

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Barbara Grant, MD, John P. Leonard, MD, Jeffrey L Johnson, Lale Kostakoglu, Eric Hsi, MD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH, Sin-Ho Jung, Bruce D. Cheson, MD

Blood (2010) 116 (21): 427.

https://doi.org/10.1182/blood.V116.21.427.427

Published: 2010

Journal Articles

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].

Myron S. Czuczman, MD, John P. Leonard, MD, Jeffrey L Johnson, Sin- Ho Jung, Eric Hsi, MD, John C. Byrd, MD, Bruce D. Cheson, MD

Blood (2008) 112 (11): 1003.

https://doi.org/10.1182/blood.V112.11.1003.1003

Published: 2008

Journal Articles

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Kristie A. Blum, MD, Jeffrey L Johnson, Sin-Ho Jung, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2008) 112 (11): 232.

https://doi.org/10.1182/blood.V112.11.232.232

Published: 2008

Journal Articles

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Eric D Hsi, MD, Jonathan Said, Jeffrey L Johnson, Sinho Jung, Raymond Lai, MD, Dan Jones, MD, PhD, Amy Chadburn, MD, Bruce D. Cheson, MD, Wyndham H. Wilson

Blood (2008) 112 (11): 476.

https://doi.org/10.1182/blood.V112.11.476.476

Published: 2008

Journal Articles

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Lale Kostakoglu, MD, MPH, David J. Straus, MD, Heiko Schöder, MD, Ann S. LaCasce, MD, Nancy L Bartlett, MD, Nathan Hall, MD, PhD, Jeffrey L Johnson, PhD, Sin-Ho Jung, PhD, George P. Canellos, MD, Lawrence H Schwartz, MD, Bruce D. Cheson, MD

Blood (2008) 112 (11): 1460.

https://doi.org/10.1182/blood.V112.11.1460.1460

Published: 2008

Journal Articles

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven E. Coutre, Richard M. Stone, Alison T. Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

Blood (2007) 109 (12): 5136–5142.

https://doi.org/10.1182/blood-2006-11-056754

Published: 2007

Journal Articles

Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.

Asad Bashey, MD, PhD, Kouros Owzar, PhD, Jeffrey L. Johnson, Steven M. Devine, MD, Richard K. Shadduck, MD, Thomas C. Shea, MD, Charles Linker, MD

Blood (2006) 108 (11): 3122.

https://doi.org/10.1182/blood.V108.11.3122.3122

Published: 2006

Journal Articles

Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.

Sonali M. Smith, MD, Jeffrey L. Johnson, MS, Donna Niedzwiecki, PhD, J. Paul Eder, MD, George P. Canellos, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2004) 104 (11): 2500.

https://doi.org/10.1182/blood.V104.11.2500.2500

Published: 2004

NARROW

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202

Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R].

Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502

Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study.

Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only